|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||46.01 / 63.74|
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Opdivo (nivolumab) for the treatment of unresectable advanced or recurrent gastric...
Bristol-Myers Squibb Company (NYSE:BMY) will take part in Leerink Partners Rare Disease & Immuno-Oncology Roundtable Conference on Thursday, September 28, 2017, in New York.
New research released today by The Economist Intelligence Unit (EIU), a division of The Economist and a leader in global business intelligence, revealed that on average, more than 75 percent of people aged 65 and older...
The drug-maker's stock just keeps going higher. What is the next move?
The indices may need a rest, but stock-pickers have an edge.
Pharma giant aims to develop cancer drug delivery technology. Halozyme shares are up more than 16% in pre-market trading.
Bristol-Myers Squibb Company (NYSE:BMY) and Halozyme Therapeutics, Inc.
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-nine cents ($0.
Bristol-Myers Squibb Company (NYSE:BMY) today announced that its Board of Directors has elected Karen Vousden, Ph.
The New Haven, Conn.-based firm on Sept. 9 received a termination notice regarding its license and collaboration pact with Johnson & Johnson's Janssen Pharmaceuticals Inc. on hepatitis C.
Bristol-Myers Squibb Company (NYSE: BMY) announced today that treatment with Opdivo (nivolumab) 3 mg/kg resulted in a significant improvement in recurrence-free survival (RFS) compared to Yervoy (ipilimumab) 10...
Bristol-Myers Squibb Company (NYSE:BMY) announced today results from the Phase 3 CheckMate -214 trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus sunitinib in patients with previously untreated advanced...
Bristol-Myers Squibb Company (NYSE:BMY) today announced three-year overall survival (OS) data from CheckMate -017 and CheckMate -057, two pivotal Phase 3 randomized studies evaluating Opdivo versus docetaxel in...
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has completed the previously announced planned acquisition of IFM Therapeutics.
Bristol-Myers Squibb Company (NYSE:BMY) announced today that a Phase 3 study evaluating Opdivo plus Yervoy in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) met its co-primary...
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2017 on Thursday, October 26, 2017.
The first of seven teams of Bristol-Myers Squibb (NYSE:BMY) employees mounted their bikes in Cannon Beach, OR, today to kick off the 2017 Coast 2 Coast 4 Cancer Ride.
Corporations have contributed at least $141.3 million to aid Hurricane Harvey relief efforts, as of Friday.
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Morgan Stanley 2017 Global Health Care Conference on Monday, September 11, 2017, in New York.
Cramer reflects on good news stirring a sneaky rally, and how Wells Fargo needs outside leadership.
More Immunotherapy Buyouts Likely After Kite Sale
Check out these three big movers today.
Prices have test $60 several times, but this looks like the real deal.
Bristol-Myers Squibb Company (NYSE:BMY) today announced more than 60 presentations, including seven late-breaking abstracts, from its Oncology portfolio will be featured at the European Society for Medical Oncology...
We are also seeing some stocks that are just too strong for their own good.
Our strategy has captured some time decay on the short call and a lift on the long call side.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.